On Friday, Shares of Capital One Financial Corporation (NYSE:COF), lost -13.12% to $78.86.
Capital One Financial Corporation declared net income for the second quarter of 2015 of $863 million, or $1.50 per diluted common share, contrast to the first quarter of 2015 with net income of $1.2 billion, or $2.00 per diluted common share, and the second quarter of 2014 with net income of $1.2 billion, or $2.04 per diluted common share. Net income for the second quarter of 2015, adjusted for the impact of restructuring charges of $147 million and a build in the U.K. PPI reserve of $78 million, was $1.0 billion or $1.78 per diluted common share.
“Capital One continues to deliver attractive risk-adjusted returns recently and invest to sustain growth and returns over the long term,” said Richard D. Fairbank, Chair and Chief Executive Officer. “We remain compelled by the opportunity, need, and urgency of digital transformation, and we continue to see growth opportunities across our businesses, particularly in Domestic Card. Capital One is well positioned to sustain attractive shareholder returns over the long term.”
Capital One Financial Corporation operates as the bank holding company for the Capital One Bank (USA), National Association (COBNA); and Capital One, National Association (CONA), which provide various financial products and services in the United States, the United Kingdom, and Canada.
Shares of Abbott Laboratories (NYSE:ABT), declined -0.29% to $51.05, during its last trading session.
The organizers of the BMW BERLIN-MARATHON recently proudly declared a new partnership with the global healthcare company Abbott (ABT), which became an Official Sponsor of the 2015 BMW BERLIN-MARATHON, one of six iconic races in the Abbott World Marathon Majors series.
With more than 2,500 employees in Germany at seven locations nationwide, Abbott is devoted to developing products and technologies that improve health and make life better. Through its sponsorship of the 2015 BMW BERLIN-MARATHON, Abbott will celebrate how people can do more, achieve more and experience more through their best health.
Abbott’s sponsorship will come to life in a number of ways. For the 40,000 registered participants – counting more than 30 Abbott employees from around the world – the company will have a “Cheer Zone” at the 38 kilometer point of the course, providing a welcome boost as runners push through to the finish line. Nearly 100 Abbott employees from its Wiesbaden location will show up to encourage athletes to achieve their race-day aims.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
Finally, CytRx Corporation (NASDAQ:CYTR), ended its last trade with 2.50% gain, and closed at $2.87.
CytRx Corporation declared the closing of its formerly declared underwritten public offering. The gross proceeds from its sale of 10,465,000 shares of common stock at a public offering price of $2.75 per share, counting 1,365,000 shares sold following the full exercise of the underwriters’ option to purchase additional shares, were about $28.8 million preceding to deducting underwriting discounts and commissions and offering expenses payable by CytRx.
CytRx intends to use the net proceeds of the offering to fund clinical trials of its drug candidate aldoxorubicin and its drug discovery activities and for general corporate purposes, which may comprise pre-commercialization activities regarding aldoxorubicin, working capital, capital expenditures, research and development and other commercial expenditures.
Jefferies LLC acted as the sole book-running manager for the offering. Oppenheimer & Co. Inc., Aegis Capital Corp., FBR Capital Markets & Co., and H.C. Wainwright & Co. acted as co-lead managers for the offering.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
